This follows the resignation of William Pinon as the company’s president and CEO and as a member of the board of directors as of the same date.
Mr Pinon has agreed to remain with the company through July 25, 2008 to assist in the executive transition process.
Mr Leonhardt said: “I look forward to a greater level of involvement as we continue to pursue regulatory approval and commercialization of this therapy to treat congestive heart failure patients, as well as, drive the development of future generation products. We look to the future with great anticipation.”